Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | BAD | Q92934 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31566360 | 1.00 | CES1 (0.37) | CES1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL22471754 | 0.90 | CES1 (0.35) | CES1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL31438411 | 0.86 | MEN1 (0.43) | CES1NPC1RAB9ANPSR1BCL2L1 | |
| SCHEMBL1044167 | 0.86 | MEN1 (0.43) | CES1NPC1RAB9ANPSR1BCL2L1 | |
| SCHEMBL1040530 | 0.83 | CES1 (0.40) | CES1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL665033 | 0.82 | DRD1 (0.39) | CES1BCL2L1BADDRD1 | |
| SCHEMBL29424782 | 0.82 | DRD1 (0.39) | CES1BCL2L1BADDRD1 | |
| SCHEMBL29924184 | 0.82 | DRD1 (0.39) | CES1BCL2L1BADDRD1 | |
| SCHEMBL26550837 | 0.82 | DRD1 (0.38) | CES1BCL2L1BADALDH1A1DRD1 | |
| Iodide SCHEMBL9231383 | 0.81 | DRD1 (0.38) | CES1BCL2L1BADDRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1650207-B1 | Process for producing optically active 3-quinuclidinols | TAKASAGO PERFUMERY CO LTD (JP) | 2007-06-27 | — | — | EP | claimed |
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | KYOWA PHARMA CHEMICAL CO., LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-3950672-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | Kyowa Pharma Chemical Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-3199513-B1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | TAKASAGO PERFUMERY CO LTD (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-10029968-B2 | Process for producing alcohol analogue | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170297990-A1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-10-19 | — | — | US | disclosed |
| EP-3199513-A1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | Takasago International Corporation (JP) | 2017-08-02 | — | — | EP | disclosed |
| EP-2774908-B1 | METHOD FOR PREVENTING DECREASE IN OPTICAL PURITY | TAKASAGO PERFUMERY CO LTD (JP) | 2017-02-08 | — | — | EP | disclosed |
| EP-2762467-B1 | Method for producing an optically active 2-arylpiperidinium salt | TAKASAGO PERFUMERY CO LTD (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-9328079-B2 | Process for producing optically active amine | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20090036696-A1 | IRIDIUM COMPLEXES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-02-05 | — | — | US | disclosed |
| US-7462722-B2 | Process for producing optically active-3-quinuclidinols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2008-12-09 | — | — | US | disclosed |
| EP-1935896-A1 | Novel optically active biaryl phosphorus compound and production process thereof | National University Corporation Tokyo University of Agriculture and Technology (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20080139822-A1 | Novel optically active biaryl phosphorus compound and production process thereof | MAXWELL TECHNOLOGIES, INC. | 2008-06-12 | — | — | US | disclosed |
| US-7294601-B2 | Phosphines, transition metal complexes containing the same as the ligand, and process for production of optically active carboxylic acids | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| EP-1650207-B1 | Process for producing optically active 3-quinuclidinols | TAKASAGO PERFUMERY CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| US-20070060772-A1 | Phosphines, transition metal complexes containing the same as the ligand, and process for production of optically active carboxylic acids | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1698609-A1 | Process for producing an alcohol or its silyl ether | Takasago International Corporation (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1650207-A1 | Process for producing optically active 3-quinuclidinols | Takasago International Corporation (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20060047122-A1 | Process for producing optically active-3-quinuclidinols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036696-A1 | IRIDIUM COMPLEXES | HAX1, MLX, H1-0 | CES1 1950/4885NPC1 4362/4885RAB9A 3304/4885 |
| US-20070060772-A1 | Phosphines, transition metal complexes containing the same as the ligand, and process for production of optically active carboxylic acids | CCND1, CCNA1, CA2 | CES1 2749/4885NPC1 4102/4885RAB9A 1773/4885 |
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | PTGS1, PTGER1, RACK1 | CES1 1327/4885NPC1 2818/4885RAB9A 3323/4885 |
| US-20060047122-A1 | Process for producing optically active-3-quinuclidinols | DHPS, QDPR, TYR | CES1 4735/4885NPC1 4487/4885RAB9A 116/4885 |
| US-20080139822-A1 | Novel optically active biaryl phosphorus compound and production process thereof | PHOSPHO1, DHRS9, HDHD5 | CES1 1126/4885NPC1 4118/4885RAB9A 297/4885 |
| US-20170297990-A1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | ADH1A, ADH1C, ADH5 | CES1 1128/4885NPC1 4466/4885RAB9A 1824/4885 |
| US-10029968-B2 | Process for producing alcohol analogue | ADH1A, ADH1C, ADH5 | CES1 1128/4885NPC1 4466/4885RAB9A 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.